We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Gurvinder
Gill
gurvinder.gill@nihr.ac.uk
Laurna
Bullock
l.bullock@keele.ac.uk
Baksho
Kaul
baksho.kaul@nihr.ac.uk
Kim
Fitzgibbon
kim.fitzgibbon@nihr.ac.uk
Helen
Wright
h.wright1@keele.ac.uk
Laurna
Bullock
l.bullock@keele.ac.uk
Laurna
Bullock
l.bullock@keele.ac.uk
Disorders of bone density and structureInjuries to unspecified part of trunk, limb or body regionOrganic, including symptomatic, mental disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
BACKGROUND
Broken bones are sometimes caused by a condition called ‘osteoporosis’. Osteoporosis is where your bones become weaker and are more likely to break easily. People with dementia are more likely to have osteoporosis and broken bones. Broken bones can result in loss of independence, worsening of dementia and need for more support from caregivers. UK guidelines recommend that people with dementia should be prescribed osteoporosis medicines, where appropriate, to prevent broken bones. However, people with dementia are not often offered these medicines, or do not stay on them long enough for them to be effective. First-line osteoporosis tablet medicines have special instructions on how they should be taken, which can be challenging for people with dementia, and they may be more likely to experience side-effects. Alternatively, osteoporosis medicines can be given by injection or infusion once every 6 months or once a year. This can take place in-hospital, or, in some areas, in the patient’s home.
AIMS AND METHODS
Interviews will be completed with people with dementia and relatives/friends of people with dementia. Interviews or focus groups will be completed with health and social care professionals and managers. Interviews and focus groups aim to explore peoples’:
•experiences of deciding about, and receiving different osteoporosis medicines, in different settings (e.g. at home, in hospital).
•barriers and enablers to offering non-tablet osteoporosis medicines, at home or in-hospital, to people with dementia.
OUTPUTS
Interviews and focus groups will inform the development of resources to support people with dementia to be offered and make decisions about osteoporosis medicines that fit best for them and their lives. The potential benefits of these resources are:
•Increased access to more osteoporosis medicine options
•Improved shared decision-making
•More likely to start and continue osteoporosis medicines
•Fewer broken bones with associated disability and deaths
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
Participants will be excluded if they are : 1) unable to verbally communicate their willingness to take part in the study 2) under 18 years old.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Laurna
Bullock
l.bullock@keele.ac.uk
Gurvinder
Gill
gurvinder.gill@nihr.ac.uk
Kim
Fitzgibbon
kim.fitzgibbon@nihr.ac.uk
Laurna
Bullock
l.bullock@keele.ac.uk
Laurna
Bullock
l.bullock@keele.ac.uk
Baksho
Kaul
baksho.kaul@nihr.ac.uk
Helen
Wright
h.wright1@keele.ac.uk
The study is sponsored by University of Keele and funded by NIHR Academy .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 60546
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
